Bicara Therapeutics (BCAX)

• Market cap: $810M
• 1 day: 3.65%
• 5 days: 0%
• 1 month: -14.62%
• 3 months: 29.54%
• 6 months: 7.88%
• Year to date: -12.7%
• 1 year: -33.57%
• 5 years: -36.86%
• 10 years: -36.86%
• Sector: Healthcare
• Industry: Biotechnology

About: Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.